Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
Blood · 29.02.2024 · 143 (9) · 796-806
DOI: 10.1182/blood.2022018971 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Blood, erschienen am 29.02.2024. Verfasst von Andrew D Leavitt und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Hemophilia A, Hemostatics. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Patients with hemophilia A require exogenous factor VIII (FVIII) or nonfactor hemostatic agents to prevent spontaneous bleeding events. Adeno-associated virus (AAV) vector–based gene therapy is under clinical investigation to enable endogenous FVIII production. Giroctocogene fitelparvovec is a recombinant AAV serotype 6 vector containing the coding sequence for the B-domain–deleted human F8 gene. In the ongoing phase 1/2, dose-ranging Alta study, 4 sequential cohorts of male participants with severe hemophilia A received a single IV dose of giroctocogene fitelparvovec. The primary end points are safety and changes in circulating FVIII activity. Interim results up to 214 weeks after treatment for all participants are presented. Eleven participants were dosed. Increases in alanine and aspartate aminotransferases were the most common treatment-related adverse events (AEs), which resolved with corticosteroid administration. Two treatment-related serious AEs (hypotension and pyrexia) were reported in 1 participant within 6 hours of infusion and resolved within 24 hours after infusion. At the highest dose level (3 × 1013 vg/kg; n = 5), the mean circulating FVIII activity level at week 52 was 42.6% (range, 7.8%-122.3%), and at week 104 it was 25.4% (range, 0.9%-71.6%) based on a chromogenic assay. No liver masses, thrombotic events, or confirmed inhibitors were detected in any participant. These interim 104-week data suggest that giroctocogene fitelparvovec is generally well tolerated with appropriate clinical management and has the potential to provide clinically meaningful FVIII activity levels, as indicated by the low rate of bleeding events in the highest dose cohort. This trial was registered at www.clinicaltrials.gov as #NCT03061201.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California San Francisco, San Francisco, CA.
- Washington Center for Bleeding Disorders and the University of Washington, Seattle, WA.
- UAMS at Arkansas Children's Hospital, Little Rock, AR.
- University of South Florida, Tampa, FL.
- University of Miami Miller School of Medicine, Miami, FL.
- Hemophilia Treatment Center, University of California Davis, Sacramento, CA.
ORCID-Profile: Barbara A Konkle, Liching Cao
Zitieren
APA
Leavitt, A. D., Konkle, B. A., Stine, K. C., Visweshwar, N., Harrington, T. J., Giermasz, A., Arkin, S., Fang, A., Plonski, F., Yver, A., Ganne, F., Agathon, D., Resa, M. L. A., Tseng, L. J., Di Russo, G., Cockroft, B. M., Cao, L., & Rupon, J. (2024). Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study. Blood, 143(9), 796-806. https://doi.org/10.1182/blood.2022018971
Vancouver
Leavitt AD, Konkle BA, Stine KC, Visweshwar N, Harrington TJ, Giermasz A, et al. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study. Blood. 2024;143(9):796-806. doi:10.1182/blood.2022018971
BibTeX
@article{Leavitt2024,
author = {Leavitt, Andrew D and Konkle, Barbara A and Stine, Kimo C and Visweshwar, Nathan and Harrington, Thomas J and Giermasz, Adam and Arkin, Steven and Fang, Annie and Plonski, Frank and Yver, Anne and Ganne, Florence and Agathon, Delphine and Resa, Maria de Los Angeles and Tseng, Li-Jung and Di Russo, Gregory and Cockroft, Bettina M and Cao, Liching and Rupon, Jeremy},
title = {Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study},
journal = {Blood},
year = {2024},
volume = {143},
number = {9},
pages = {796--806},
doi = {10.1182/blood.2022018971}
}
EUVIMED